Comparative antirelapse efficacy of  CDRI compound 80/53 (Bulaquine) vs primaquine in double blind clinical trail

Valecha, Neena; Adak, T; Bagga, A K; Asthana, O P; Srivastava, J S; Joshi, Hema; Sharma, V P

dc.contributor.author	Valecha, Neena
dc.contributor.author	Adak, T
dc.contributor.author	Bagga, A K
dc.contributor.author	Asthana, O P
dc.contributor.author	Srivastava, J S
dc.contributor.author	Joshi, Hema
dc.contributor.author	Sharma, V P
dc.date.accessioned	2009-09-08T09:02:25Z
dc.date.available	2009-09-08T09:02:25Z
dc.date.issued	2001
dc.identifier.citation	Current Science-2001, 80, 561-563	en
dc.identifier.uri	http://hdl.handle.net/123456789/508
dc.description.abstract	One year follow-up of malaria patients was under-taken to minitor the antirelapse efficacy of CDRI compound 80/53 (Bulaquine).a total of 697 patients of plasmodium vivax malaria were included in three arm double blind randomized study comparing CDRI 80/53 with placebo and primaquine. Drugs were givan once a day for 5 days and the dose for CDRI 80/53 and primaquine was 25 mg and 15 mg, respectively. Thirty-four patients were lost to follow-up and 663 patients completed one year trail. Two hundred and fourteen patients came back with second episode during the one-year followup period. A detailed analysis revealed that the relapse rate during non-transmission period with placebo in 16 (10.6%) patients was higher than both in primaquine (3.0%) and CDRI 80/53 (4.9%) groups.	en
dc.format.extent	33746 bytes
dc.format.mimetype	application/pdf
dc.language.iso	en	en
dc.title	Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vs primaquine in double blind clinical trail	en
dc.type	Article	en